Promoting adverse drug reaction reporting: comparison of different approaches

Abstract

OBJECTIVE To describe different approaches to promote adverse drug reaction reporting among health care professionals, determining their cost-effectiveness.METHODS We analyzed and compared several approaches taken by the Northern Pharmacovigilance Centre (Portugal) to promote adverse drug reaction reporting. Approaches were compared regarding the number and relevance of adverse drug reaction reports obtained and costs involved. Costs by report were estimated by adding the initial costs and the running costs of each intervention. These costs were divided by the number of reports obtained with each intervention, to assess its cost-effectiveness.RESULTS All the approaches seem to have increased the number of adverse drug reaction reports. We noted the biggest increase with protocols (321 reports, costing 1.96 € each), followed by first educational approach (265 reports, 20.31 €/report) and by the hyperlink approach (136 reports, 15.59 €/report). Regarding the severity of adverse drug reactions, protocols were the most efficient approach, costing 2.29 €/report, followed by hyperlinks (30.28 €/report, having no running costs). Concerning unexpected adverse drug reactions, the best result was obtained with protocols (5.12 €/report), followed by first educational approach (38.79 €/report).CONCLUSIONS We recommend implementing protocols in other pharmacovigilance centers. They seem to be the most efficient intervention, allowing receiving adverse drug reactions reports at lower costs. The increase applied not only to the total number of reports, but also to the severity, unexpectedness and high degree of causality attributed to the adverse drug reactions. Still, hyperlinks have the advantage of not involving running costs, showing the second best performance in cost per adverse drug reactions report.

Risk of drug interactions and prescription appropriateness in elderly patients

“…It is estimated that approximately 5% of hospital admissions are due to ADRs, and that they cause around 197,000 deaths a year at European level. For patients over the age of 75, hospital admission due to an ADR may even be 1 in every 3 [5,6]. DDI (Drug-drug interactions) represent another problem of the elderly patient.…”

Personalized Medicine and Adverse Drug Reactions: The Experience of An Italian Teaching Hospital

“…The first step for a correct management of the problem is to form an adequate pharmacovigilance system with the purpose to promptly report all serious ADRs that may especially occur after the drug is placed in the market [40,41].…”

Pharmacovigilance: Present Scenario and Future Goals

“…[22][23][24] Newness to pharmacovigilance, a low dimension of ADR-detailing abilities, an absence of learning joined with negative demeanors like obliviousness, fear legitimate risk and absence of significance are believed to be identified with the current deficient reaction to numerous ADRs. [25][26][27][28] A few mediations (actualizing conventions, instructive workshops, or continued messaging or phone calls) have been executed trying to enhance the fitness of social insurance experts, [29][30][31][32] yet these intercessions are exorbitant or neglect to deliver clinically applicable and long-haul impacts. 23…”